Get Flat 15% Discount on ED Drugs for orders value $70 or more
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      India emerging drug R&D hub


      India is gearing to become a large pharmaceutical research and development (R&D) destination, with multinational companies such as Merck and Eli Lilly moving projects to India and domestic companies such as GVK Biosciences and Jubilant Organosys investing in providing related services.Speaking to Business Line on the sidelines of the World Economic Forum, D.S. Brar, Chairman, GVK Biosciences, said: "We are providing R&D services to 20 pharma and seven biotech companies. We have already set up pharma KPO (knowledge process outsourcing) centres in Chennai and Delhi. In future, we could enter into collaborations with other companies in drug discovery on a risk-reward sharing arrangement." The company has invested about Rs 60 crore in the business and will invest an equal amount in the coming months.

      Similarly, Jubilant Organosys plans to scale up its contract research business. "Currently, we are conducting only bio-equivalence or Phase I studies. But after the acquisition of US-based company, Target, and merging it with our own existing entity, we hope to enter into the front-end of the business," said Hari S. Bhartia, Co-Chairman and Managing Director, Jubilant. He said that currently companies conduct trials in the US, Europe and Asian markets. "We want them to include India as a site for clinical trials," he added.Meanwhile, multinational companies are excited about the prospects of moving some part of their R&D to India. Richard A. Smith, Strategy Consultant, Intercontinental Region, Eli Lilly, said, "We would like to tap the intellectual capital available in India and have done some clinical studies here. We are looking at different types of R&D opportunities and models and have initiated some discussions with companies." Some of the therapeutic segments that the company is looking at for R&D in India include oncology, Diabetes, mental health diseases and so on.

      MSD Pharmaceuticals India (a subsidiary of US-based Merck & Co) too plans to launch clinical studies of an existing Asthma drug for new indications. "Almost all the companies here have spoken to us and we are open to conducting research studies of both new molecules and new indications for existing molecules. MSD is also willing to forge partnerships with government-run research centres such as ICMR and CSIR," added, Leonard Tauro, Managing Director, MSD.

      November 29, 2005


      Share this Article!

    Back to top^